INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

INMB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

INmune Bio, Inc.NASDAQ: INMB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $3.64M fell 52.3% year over year, behind the -48.1% change in trailing-twelve-month research & development. Sequentially, it rose 56.3% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.

Context

  • Research & development amounted to 41318.0% of revenue in FY2025, down 195582.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -52.3% toward the trailing-twelve-month pace of -48.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.64M+56.3% QoQ
Last fiscal yearDec 2025
$20.66M-37.7% YoY
LTMMar 2026
$16.66M-48.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.3%——
1 year-37.7%——
3-year CAGR+6.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
20.66M USD
Year-over-year change
-37.7%
4-year CAGR
+0.1%

Research & Development vs competitors

How INMB compares with its peers on the latest reported figures

  • INMB's LTM Mar 2026 research & development of $16.66M is the 3rd highest of the 4 companies compared; the peer median is $46.96M.
  • Its year-over-year change of -48.1% is the lowest of 4, against a peer median of -23.2%.
  • Over three fiscal years its annual growth of +6.6% compares with a peer median of +5.8%.
INMB Competitors Peer median
Research & Development for INMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$69.45M -12.9%+5.8%770.4%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$46.96M -24.3%+23.1%—
INMBINmune Bio, Inc.LTM Mar 2026$16.66M -48.1%+6.6%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$16.65M -23.2%-13.5%—
Peer median (excluding INMB) $46.96M-23.2%+5.8%770.4%

Competitors are the stored peer set for INMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue181K374K155K14K50K
Cost of Revenue00000
Gross Profit181K374K155K14K50K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development20.54M17.07M20.27M33.17M20.66M
Selling, General & Admin8.79M9.26M9.62M9.48M10.26M
Operating Expenses29.33M26.33M29.9M42.65M30.92M
Depreciation & Amortization29.15M25.95M29.74M553K84K
EBITDA(1.19M)(1.35M)(267K)(41.53M)(45.85M)
EBITDA Margin-655.8%-360.4%-172.3%-296635.7%-91698.0%
Operating Income(29.15M)(25.95M)(29.74M)(42.64M)(30.87M)
Operating Margin-16106.6%-6938.8%-19187.7%-304535.7%-61738.0%
Interest Income0000850K
Interest Expense00000
Other Income / Expenses(1.19M)(1.35M)(267K)553K(15.06M)
Income Before Tax(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Pre-Tax Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
Income Tax Expense00000
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Net Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
EPS (Basic)(1.88)(1.52)(1.67)(2.11)(1.86)
EPS (Diluted)(1.88)(1.52)(1.67)(2.11)(1.86)
Weighted Avg Shares16.13M17.93M17.98M19.94M26.59M
Weighted Avg Shares (Diluted)16.13M17.93M17.98M19.94M26.59M

INmune Bio, Inc.

NASDAQ:INMB

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.